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Molecular Imaging of the Human Pulmonary Vascular
Endothelium Using an Adrenomedullin Receptor Ligand
Franc¸ois Harel, Xavier Levac, Quang T. Nguyen, Myriam Le´tourneau, Sophie Marcil, Vincent Finnerty,
Marie`ve Cossette, Alain Fournier, and Jocelyn Dupuis
Abstract
This phase I study (NCT01539889) evaluated the safety, efficacy, and dosing of PulmoBind for molecular imaging of pulmonary
circulation. PulmoBind is a ligand of the adrenomedullin receptor abundantly distributed in lung capillaries. Labeled with 99mTc, it
allows single-photon emission computed tomographic (SPECT) imaging of lung perfusion. In preclinical studies, PulmoBind scans
enabled detection of lung perfusion defects and quantification of microcirculatory occlusion caused by pulmonary hypertension.
Healthy humans (N 5 20) were included into escalating groups of 5 mCi (n 5 5), 10 mCi (n 5 5), or 15 mCi (n 5 10) 99mTc-PulmoBind.
SPECT imaging was serially performed, and 99mTc-PulmoBind dosimetric analysis was accomplished. The radiochemical purity of
99mTc-PulmoBind was greater than 95%. There were no safety concerns at the three dosages studied. Imaging revealed predominant
and prolonged lung uptake with a mean peak extraction of 58% 6 7%. PulmoBind was well tolerated, with no clinically significant
adverse event related to the study drug. The highest dose of 15 mCi provided a favorable dosimetric profile and excellent imaging.
The postural lung perfusion gradient was detectable. 99mTc-PulmoBind is safe and provides good quality lung perfusion imaging. The
safety/efficacy of this agent can be tested in disorders of pulmonary circulation such as pulmonary arterial hypertension.
C URRENTLY, only one agent is approved in nuclearmedicine to study lung circulation: macroaggregates of
albumin labeled with 99mTc (99mTc-MAA). 99mTc-MAA is
used almost exclusively to detect large pulmonary perfusion
defects caused by embolism. Since this agent is larger than
small pulmonary vessels, after injection, it is physically trapped,
which enables external detection. The potential limitations of
99mTc-MAA therefore include the inability to image the small
pulmonary circulation beyond the point of obstruction,
limiting its sensitivity to detect small vascular defects such as
those caused by pulmonary arterial hypertension, as well as
potential infectious risks because this agent is derived from
human albumin. Another limitation is that approximately
350,000 particles of this tracer are injected and block as
many pulmonary vessels in the process. This undesirable
‘‘physical’’ blockage of pulmonary circulation in subjects
with an already compromised pulmonary circulation
represents a current warning on the product monograph.
Furthermore, the product may be allergenic in subjects
sensitive to albumin and presents supply issues as it is
derived from human albumin. Replacement agents that
would provide functional assessment of lung perfusion
without these caveats are desirable. Molecular imaging
agents targeting the pulmonary vascular endothelium
have been evaluated for this purpose.1
Adrenomedullin is a 52–amino acid multifunctional
regulatory peptide expressed in a wide range of tissues,
including the lungs.2–4 Its specific heterodimeric receptor is
composed of the calcitonin-like receptor (CLR) and the
receptor activity–modifying protein 2 or 3 (RAMP2,
RAMP3).5 The receptor is abundantly expressed in human
alveolar capillaries and mostly distributed at the surface of
the endothelium.6–8 Accordingly, the lungs contain adre-
nomedullin binding sites at a density higher than that for
any other organ studied8,9 and are a primary site for
adrenomedullin clearance.10,11 We hypothesized that radi-
olabeled adrenomedullin derivatives could be used as tracers
to evaluate the integrity of pulmonary circulation. Through
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rational design and structure-activity studies, we developed
various derivatives12 that would maintain binding affinity
without significant biologic effects while enabling the
addition of a chelating moiety for a suitable radioisotope.13
These derivatives demonstrated good-quality lung imaging,
enabling the detection of large perfusion defects mimicking
pulmonary embolism,14 but also microcirculatory occlusion
in a model of pulmonary arterial hypertension.15 A lead
compound possessing the desired properties was devel-
oped,13 called PulmoBind. This phase I trial tested the safety
and efficacy of PulmoBind.
Materials and Methods
The trial was conducted at the Montreal Heart Institute
and registered at ClinicalTrials.gov (NCT01539889). The
study was approved by the Ethics Committee (No. CER
08-1062) and conducted in accordance with the amended
Declaration of Helsinki. All participants signed a written
informed consent form.
PulmoBind synthesis was performed as previously
described.13 The Fmoc- (polyethylene glycol)4-COOH used
as a spacer in the peptide synthesis was purchased from
Quanta Biodesign Ltd. Disulfide bond formation to yield a
cyclic derivative was performed by overnight air oxidation
after dissolution of the linear peptide in an aqueous solution
(pH 8.8) at a concentration of 0.1 mg/mL. The peptide was
purified by reversed-phase high-performance liquid chro-
matography (RP-HPLC). The amino acid sequence of
PulmoBind, in comparison with that of native human
adrenomedullin (hAM), is shown in Figure S1 (online
version only). The purity of the final product was evaluated
by analytical RP-HPLC (. 98%), and matrix-assisted laser
desorption ionization–time-of-flight mass spectrometry
(MALDI-ToF MS; Voyager DE, Applied Biosystems) was
used to confirm the right mass of the synthetic product (m/
ztheo: 4270.82; m/zobs: 4271.71).
Unidose vials were prepared containing 18.5 mg of
lyophilized PulmoBind. The labeling procedure was
performed by the addition of 20 mL acetate buffer (1 M,
pH 5.5), 200 mL Na3PO4 (0.1 M, pH 12), 31.25 mL SnCl2
(0.8 mg/mL in HCl 0.05M), and 30 mCi of Na99mTcO4
(28.9 pmol). Finally, 1 mL of NaH2PO4 (0.1 M, pH 4.5)
was added to adjust the pH to 7.4. 99mTc-PulmoBind was
purified using a C18 Sep-Pak cartridge, and radiochemical
purity was tested by instant thin-layer chromatography.
Radiometric and ultraviolet (UV) HPLC chromatograms
of the final drug product are shown in Figure S2 (online
version only). It appears that the radiolabeled product
exists as one product, but due to the very small quantity of
starting drug substance, the labeled product generated
through this protocol is undetectable by a UV detector.
Specific activity is estimated to be around 6.8 mCi/mmol,
and the average radiochemical yield was 53.6% 6 4.5%.
There were three study objectives: safety, efficacy and
dosing. A safety objective aimed to determine pharma-
cokinetics and biodistribution to perform dosimetric
evaluation; another safety objective was to evaluate any
effect on vital signs and on hematology and biochemistry
profiles and to evaluate any local or systemic reactions.
The efficacy objective was to evaluate the ability of
PulmoBind to allow lung perfusion imaging in human.
The third objective determined the optimal dose by
evaluating the safety/efficacy in three groups with
escalating dosages.
Study Design and Safety Assessments
Twenty healthy subjects were recruited. Detailed inclusion
and exclusion criteria are discussed in the Supplementary
Material (online version only).
The study timeline is shown in Figure S3 (online
version only). Study subjects were divided into three
groups receiving increasing intravenous dosages of 99mTc-
PulmoBind: group A, 5 mCi (185 MBq, n 5 5); group B,
10 mCi (370 MBq, n 5 5); and group C, 15 mCi (555
MBq, n 5 10). Study procedures were performed
according to Figure 1. All adverse events occurring during
the study were reported and characterized.
Dosimetry calculations were performed as follows. A
transmission scan was performed to obtain an attenuation
map using a cobalt-57 flood source. Whole body scans
were then obtained serially after injection (see Figure 1)
with a dual-head e-cam (Siemens Medical Systems) using
a low-energy high-resolution collimator with 256 3 1,024
matrices. Acquisitions were evaluated with MATLAB
version 7.01 (MathWorks, Natick, MA). Regions of
interest were drawn over the most visible organs from
anterior and posterior projections. Background noise was
removed from each organ’s region of interest. The
geometric mean of anterior and posterior view images
was used to calculate the estimated 99mTc total count
and mean counts dose, in counts per minute, for the
organ.
A regression model (double exponential or gamma
variate depending on the organ) was applied. Collected
urine and stool values were added to the biodistribution
calculation for the bladder and intestines, respectively, to
model a closed system. Activity in the rest of the body or
residual cumulative dose was estimated to be the
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theoretical total cumulative dose for 99mTc less the
cumulative dose of all the other organs. The final
cumulative dose for the bladder was recalculated using
OLINDA/EXM 1.0 software (Organ Level Internal Dose
Assessment Code) with the voiding bladder model using a
voiding interval of 2 and 4.8 hours. Percentage of the total
dose in the feces was used to calculate the cumulative doses
of the different parts of the digestive system with the
International Commission on Radiological Protection
gastrointestinal model provided in OLINDA/EXM software.
The dose to the ovaries was estimated from biodistribution
measured in males but applied to a female model.
Blood samples (6 mL) were obtained to deter-
mine plasma kinetics of PulmoBind using a two-phase
exponential-decay equation with GraphPad Prism version
6.0 software (GraphPad Software, La Jolla, CA).
For precise quantification of pulmonary clearance of
PulmoBind, we performed a dynamic acquisition of the
chest for 20 minutes following injection (see Figure 1)
coupled with whole body images later in time.
Lung imaging quality was determined by two nuclear
medicine specialists from whole body image acquisitions.
They graded the scans from I (mediocre) to IV (superior
quality). Quality was judged in relation to that usually
achieved with radiolabeled albumin macroaggregate lung
perfusion scans based on the investigator’s judgment.
Statistical Analysis
Analysis was performed for the three study groups
combined and for each separately. Sample size estimation
was based on blood pressure variation. Blood pressure
measured in 1,743 Canadian individuals was 121 6 16 mm
Hg (mean 6 SD) for systolic and 78 6 11 mm Hg for
diastolic.16 Based on these values and assuming a pre-/
postsystolic blood pressure correlation of 0.5, a sample size
of 20 (whole study group) allowed the detection of a
reduction of 12 mm Hg in systolic blood pressure (210%)
with a power of 90% and an alpha of 0.05. For a sample size
of 10 (group C, 15 mCi), the power to detect a reduction of
Figure 1. Nuclear medicine imaging protocol.
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18 mm Hg (215%) was 90%. For a sample size of 5 (group
A, 5 mCi, and group B, 10 mCi), the power to detect a
reduction of 24 mm Hg (220%) was 80%.
Statistical analysis was performed using SAS version 9.2
(SAS Institute, Cary, NC). The maximum reduction in
vital signs from visit 1 (preinjection) to 360 minutes was
analyzed using an analysis of variance (ANOVA) model
with study group as the main factor. Under this model, the
mean maximum reduction in the three study groups
combined and in each group separately was estimated and
presented with a 95% confidence interval (CI). In
addition, vital signs at day 1 (preinjection), 1 minute, 2
minutes, 3 minutes (during injection), 5 minutes, 15
minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5
hours, and 6 hours were analyzed using a repeated
measures ANOVA model including study group, time,
and study group 3 time interaction as the main factors.
Under this model, differences from day 1 (preinjection) to
each follow-up time point were estimated and presented
with a 95% CI. Oral temperature, hematology, and
biochemistry parameters were analyzed using a repeated
measures ANOVA model including study group, time, and
study group 3 time interaction as the main factors. The
focus of these analyses is on showing that the bounds of
the 95% CI of the change over time and maximum
reduction are within acceptable limits. Due to too low
power and the small sample size, adverse events,
categorical safety parameters, and the efficacy end point
of lung perfusion are simply tabulated. Values are reported
as mean 6 SD or as mean (95% CI).
Results
Two women and 18 men were recruited. The mean age was
33 6 14 years (range 20–71 years), and the mean weight
was 75 6 14 kg. The mean drug substance purity by HPLC
analysis and MALDI-ToF MS was . 98%. The radio-
chemical purity of 99mTc-PulmoBind was 95 6 4%. All
subjects were included into the safety analysis. In one
subject, the injected 99mTc-PulmoBind showed prolonged
forearm vein retention due to an anomalous venous return
(nonconnecting veins). This subject was therefore not
included in the plasma kinetic and biodistribution
analysis.
Plasma kinetics of PulmoBind is shown in Figure 2.
Plasma levels rapidly decreased with a distribution half-life
of 6 minutes (95% CI 4–12) and an elimination half-life of
90 minutes (95% CI 65–149).
Biodistribution was analyzed for the whole study group
(n 5 19). 99mTc-PulmoBind was rapidly retained by the
lungs, with a peak uptake of 58% 6 7% ID occurring 5.5
6 0.7 minutes following injection. Lung activity cleared
very slowly, with 44% 6 6% ID after 35 minutes and
33% 6 5% ID after 60 minutes. Whole body imaging in
anterior and posterior views with the lung activity-time
curve of a study subject is shown in Figure 3. A video
demonstrating dynamic 99mTc-PulmoBind lung uptake
and body biodistribution over 6 hours is provided in the
online version (Video S1).
Organs biodistribution is shown in Figure 4. The
majority of the tracer is retained by the lungs, followed in
intensity by the kidneys and the liver. Increased urinary,
gallbladder, and bowel activity with time confirms these
routes of elimination. Tomographic imaging at 90 minutes
is shown in Figure 5. There is still substantial lung activity,
and, interestingly, higher activity is evident in the more
gravity-dependent (dorsal) regions. A 360u animation is
shown in Video S2 (online version only).
Safety Parameters and Imaging Quality
Sample size was estimated to detect a variation of 12 mm
Hg for the whole study group (N 5 20), 24 mm Hg in the
5 mCi and 10 mCi groups (n 5 5), and 18 mm Hg in the
15 mCi group (n 5 10). These values are also deemed
clinically significant.
For the 20 subjects, the maximum reduction in blood
pressure (mm Hg) for day 1, from preinjection to 6 hours,
is 27.4 (210.3, 24.4) (mean with 95% CI) for systolic
blood pressure and 29.8 (213.4, 26.2) for diastolic blood
pressure. Mean systolic and diastolic blood pressures
measured throughout the study for the 20 subjects are
presented in Figure 6. The change in systolic and diastolic
pressures compared to preinjection values is also depicted.
The dotted lines represent a 12 mm Hg variation,
Figure 2. Plasma kinetics of 99mTc-PulmoBind in humans.
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considered to be clinically significant. Table 1 shows the
maximum reduction in systolic and diastolic blood
pressure (irrespective of its time point) and the confidence
interval for each study group. There were no clinically
significant changes. Similarly, there were no significant
variations in heart rate, respiratory rate, oxygen saturation,
and body temperature (data not shown). Biochemistry and
hematology laboratories remained within the normal
clinical range.
Activity-time curves for subjects receiving the nominal
dose of 15 mCi of 99mTc-PulmoBind are presented in
Figure 4B. About 97% of the cumulative dose can be
predicted from the organ modeling. The radiation doses
absorbed by target organs and the total body are shown in
Table 2.
Figure 3. Whole body planar SPECT
imaging in a human (subject 006)
60 minutes after injection of 99mTc-
PulmoBind (A) and activity-time curve
for the lung activity of the tracer (B).
Figure 4. A, Organ biodistribution of 99mTc-PulmoBind at various
time points after injection for all study groups combined (n 5 19). B,
Activity-time curves in the organs of nine subjects receiving 15 mCi
(555 MBq) of 99mTc-PulmoBind. Values are mean 6 SD.
Figure 5. Tomographic SPECT imaging of the lungs 90 minutes after
99mTc-PulmoBind injection in a human in transversal (A), sagittal (B),
and frontal (D) views. There is greater activity in the gravity-
dependent (dorsal) region of the lungs. Three-dimensional reconstruc-
tion is shown in C.
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There were no serious adverse events. The frequency,
relationship to the study drug, and intensity of nonserious
events are shown in Figure S4 (online version only). There
were no events definitely related to the study drug. There
was one nonserious event probably related to the study
drug as a subject experienced mild pain at the injection
site.
Imaging quality is shown in Figure 7. At the dosage of
15 mCi (555 MBq), a substantial proportion of subject
showed superior quality at both 35 minutes (60%) and 60
minutes (30%) following injection.
Discussion
PulmoBind was developed through rational design and
structure-activity studies to specifically and safely image
pulmonary circulation by binding to the adrenomedullin
receptor.13 Adrenomedullin is a 52–amino acid peptide
possessing various biologic effects, among them vasodila-
tion. Adrenomedullin may be involved in pulmonary
hypertension, and its chronic administration in animal
models resulted in therapeutic improvement.17 The lung is
a primary site for plasma adrenomedullin clearance10 and
displays a high density of receptors, mostly in alveolar
capillaries.6 Using labeled derivatives, we demonstrated
specific and important lung uptake after intravenous
injection.12 Furthermore, we demonstrated that labeled
adrenomedullin derivatives could image large lung perfu-
sion defects mimicking pulmonary embolism as well as
small pulmonary vessel obliteration in the monocrotaline
model of pulmonary arterial hypertension.14,15 In the
latter, there is also reduced pulmonary expression of the
receptor. Although human pathologic data demonstrated
important distribution of adrenomedullin binding sites in
the capillaries, this is the first in vivo demonstration that
the human lung represents a primary site for circulating
adrenomedullin clearance. The lung uptake is prolonged,
suggesting that the tracer may irreversibly bind to its
receptor to be later internalized. Previous data in dogs
were also suggestive because there was no detectable return
of ligand within a pulmonary transit time.14 The current
study therefore validates the adrenomedullin receptor as
an appealing target to noninvasively probe the integrity of
pulmonary circulation in humans.
The maximal dose of 99mTc-PulmoBind used in the
current study (15 mCi) contained a maximum of 18.5 mg
of peptide. This dosage did not cause any clinically
significant hemodynamic effect. There were no variations
in blood pressure outside the predetermined clinically
significant range. The structure of PulmoBind was indeed
designed to reduce any potential hypotensive effects
observed with adrenomedullin by substituting the four
key amino acid residues Arg17-Phe18-Gly19-Thr20 con-
tained within the cystine structure (S – S bridged Cys
16
and
Cys21) with a four-unit polyethylene glycol spacer.
Figure 6. Effect of PulmoBind on systemic blood pressure of all study
groups (N 5 20). The graph A represents mean systolic and diastolic
blood pressures. Variation of systolic (B) and diastolic (C) blood
pressure compared to preinjection values. The dotted lines represent a
12 mm Hg difference predetermined to be clinically significant.
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The dosimetry for patients selected for the nominal dose
of 15 mCi 99mTc-PulmoBind reveals an effective dose of
approximately 6 to 8 mSv. The liver and the kidneys rapidly
eliminate the activity. By comparison, the absorbed dose is
similar to single-photon emission computed tomographic
(SPECT) myocardial scintigraphy, a commonly used
diagnostic test. At the dosage of 15 mCi, 99mTc-
PulmoBind provided lung scans that were judged to be of
superior quality compared to what is generally obtained
with labeled albumin macroaggregates. For an average adult
of 70 kg, a dose of 4 mCi of 99mTc-MAA results in a lower
estimated whole body absorbed dose of 0.6 mSv, whereas
the absorbed dose to the lungs is similar to that of
PulmoBind at 8.8 mSv (Draximage MAA kit monography,
Jubilant Draximage, Quebec). At our institution, we usually
inject about 10 mCi of 99mTc-MAA to perform a lung scan.
Albumin macroaggregate injections are composed of
particles generally varying in size from 10 to 70 mm. The
number of particles injected varies but is generally around
350,000 per injection. These particles will therefore block
alveolar capillaries but also larger precapillary vessels. By
contrast, 99mTc-PulmoBind does not block vessels but
binds to the vascular endothelial cells expressing its
receptors. Since the greatest vascular surface area resides
in the alveolar capillaries, where intense adrenomedullin
binding has previously been observed in human lungs,6 use
of the molecular agent PulmoBind may provide superior
imaging. Interestingly, the normal dorsoventral postural
perfusion gradient was also easily detectable, demonstrat-
ing that PulmoBind distributes according to blood flow.
Numerous disorders can affect the physical and biologic
integrity of pulmonary circulation. Unfortunately, there is
currently no noninvasive method to directly probe the
status of pulmonary circulation. The pulmonary capillaries
represent a very large metabolically active vascular surface
area. Future trials are necessary to determine if clinical
conditions that affect the distribution, density, and/or
activity of the adrenomedullin receptor may be evaluated
using PulmoBind. More specifically, PulmoBind could be
evaluated as a noninvasive test to image pulmonary arterial
hypertension, a condition associated with endothelial
dysfunction and loss of pulmonary microcirculation.
Conclusion
This phase I study assessed the safety and efficacy of
PulmoBind, a novel lung molecular imaging agent
Table 1. Mean Maximum Reduction per Study Group for Systolic and Diastolic Pressures
Blood Pressure (mm Hg) Group Maximum Reduction 95% CI
Systolic 5 mCi* 217.2 223.0, 211.4
10 mCi{ 23.6 29.4, 2.2
15 mCi{ 24.3 28.4, 20.2
Diastolic 5 mCi* 211.4 218.7, 24.1
10 mCi{ 27.8 215.1, 20.5
15 mCi{ 210 215.1, 24.9
*185 MBq.
{370 MBq.
{555 MBq.
Table 2. Absorbed Radiation after 99mTc-PulmoBind
Target Organ Equivalent Dose (mSv/555 mBq)
Gallbladder 25.25
Kidneys 23.60
Lungs 8.01
Liver 3.97
Spleen 2.37
Bladder
2.0-hour void 12.08
4.8-hour void 28.29
Testicles
2.0-hour void 0.58
4.8-hour void 1.02
Ovaries*
2.0-hour void 6.60
4.8-hour void 7.48
Effective Dose (mSv/555 mBq)
Total body
Man 2.0-hour void 5.58
Man 4.8-hour void 6.45
Woman 2.0-hour void 6.81
Woman 4.8-hour void 7.68
*Dose to the ovaries is estimated from male biodistribution, applied to a
female dosimetry model.
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designed to noninvasively evaluate pulmonary circulation.
In this first-in-human trial, there were no safety concerns,
and PulmoBind provided very good-quality lung imaging.
This novel molecular imaging agent should now be tested
in disorders of pulmonary circulation.
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SUPPLEMENTARY MATERIAL
Molecular Imaging of the Human Pulmonary Vascular
Endothelium Using an Adrenomedullin Receptor Ligand
Franc¸ois Harel, Xavier Levac, Quang T. Nguyen, Myriam Le´tourneau, Sophie Marcil, Vincent Finnerty,
Marie`ve Cossette, Alain Fournier, and Jocelyn Dupuis
Supplementary Material
Inclusion Criteria
1. Male and female subjects greater than 18 years of age.
Female subjects must be postmenopausal (defined as 2
years after the last menstrual cycle).
2. Baseline measurements must be in the limit of normal
for the following:
a. Blood pressure: systolic 100 to 140 mm Hg, and
diastolic 50 to 90 mm Hg
b. Heart rate: 60 to 100 beats per minute
c. Oral temperature: , 37.6uC
d. Respiratory rate: 12 to 20 breaths per min
e. Lung function tests
f. Echocardiogram, including estimation of pulmon-
ary artery systolic pressure
g. Chest radiograph
h. Electrocardiogram
Exclusion Criteria
1. Any known chronic or acute medical condition with or
without the need for chronic pharmacologic therapy or
any condition that may interfere with normal biodis-
tribution of DFH-12. This includes but is not restricted
to lung parenchymal or lung vascular diseases such as
chronic obstructive pulmonary disease, bronchitis,
lung cancer, pleural effusion, emphysema, asthma,
pulmonary fibrosis, occupational lung disease, pul-
monary hypertension (primary or secondary), systemic
hypertension, diabetes, cancer, kidney disease, liver
disease, heart failure or previous myocardial infarction,
coronary artery disease, peripheral vascular disease, or
inflammatory disease.
2. Subjects requiring chronic administration of any
substance for a medical condition
3. Active smoking or history of smoking for more than 1
year in the past 10 years
4. Known self-reported alcoholism (active or abstinent).
Subjects with possible alcohol dependence will com-
plete the Michigan Alcohol Screening Test (MAST)
and will be excluded if the score is $ 6.
5. Unable to tolerate study procedures (e.g., venipunc-
ture, movement restrictions during imaging)
6. Previous nuclear study since 1 week (to avoid cross-
contamination)
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Figure S1. Amino acid sequences of
human adrenomedullin and PulmoBind.
The color blue depicts residues from the
endogenous peptide sequence (human
adrenomedullin), orange the 99mTc-
chelating moiety, and gray the polyethy-
lene glycol–4 spacer substituting the four
intracyclic residues. The International
Union of Pure and Applied Chemistry
(IUPAC) one-letter code was used to
identify amino acids, with uppercase and
lowercase letters associated with L and D
configuration, respectively.
Figure S2. HPLC elution profiles of (A)
PulmoBind (14.4 mM, tR 5 15.8 min)
and (B) 99mTc-PulmoBind (1.44 mM) as
observed with a UV detector set at
220 nm, with (C) corresponding signals
collected from the radiometric detector
mounted to the UV detector outlet. For
each analysis, 20 mL was injected onto a
C18 Waters X-Bridge BEH column
(3.5 mm, 3.0 3 150 mm) connected to
a system composed of 2 Waters 501
Pumps, a Waters 2707 autosampler, a
Waters 2998 Photodiode Array (PDA)
detector, and an Eckert & Ziegler Flow
Count Base Fc-1000 radiometric detec-
tor. Elution was achieved by a linear
gradient from 3 to 40% acetonitrile in
water containing 0.1% trifluoroacetic
acid.
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Figure S3. Study timeline.
Figure S4. Study adverse events. Top
figure: Frequency of adverse events and
relationship to PulmoBind. Bottom
figure: Frequency of adverse events
and intensity.
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Video S1. Dynamic uptake of 99mTc-PulmoBind in humans over 6
hours following intravenous injection.
Video S2. Tomographic reconstruction of lung imaging with 99mTc-
PulmoBind 90 minutes after injection.
4 Harel et al
